Accure's TiMES technology integrates multiplex automation, electronic detection and machine learning into compact systems to accelerate biomarker/target discovery and testing. By converting molecular data from biological fluid directly into electrical signals, Accure bypasses the limitations of existing optical diagnostic devices and significantly improves the speed and sensitivity of its tests. 

 

The technology was initially developed at the Harvard Medical School and Massachusetts General Hospital. Together with clinical and industry partners, Accure has developed unique solutions for cancer, neurodegeneration and other complex diseases.